The whole stock comes down to one event: the EAAA Alternatives IPO.

• Bull ($1.97). Three external buyers have already cash-validated the children — Carlyle paid $225M for 45% of Nido (Feb 2026), WestBridge $48M for 15% of the AMC, Nuvama monetised at $380M in FY25. Sum-of-parts arithmetic anchors a 4× P/B re-rating.
• Bear ($0.75). Edelweiss earns 8.7% ROE and trades at 2.65× book; same-ROE peer JM Financial trades at 1.27×. Compression to the NBFC peer band is a 44% drawdown, before any further markdown for the regulator overhang.
• The print that decides. EAAA's revised DRHP cleared SEBI on 23 April 2026, opening a 12-month listing window. A list at or above DRHP-implied platform value confirms the unlock; a >25% repricing or withdrawal breaks the bull case in a single print.

The EAAA platform mark consensus is using is roughly half the actual cash print.

• The hard mark. On 10 March 2026, Edelweiss placed 4.4% of EAAA with existing limited partners and select investors for $40M — an arithmetic platform value of ~$905M. No published broker target reflects this transaction.
• The consensus anchor. Sell-side targets ($1.15–1.33) and the bull-bear ledger anchor to the DRHP-implied band of $425M–$535M — derived from the offer-for-sale sizing, not a real transaction.
• What it implies. Edelweiss retains ~95% of EAAA. At the secondary mark, that residual stake alone is worth ~$855M — 68% of today's market cap before the mutual fund, residual Nido, the ARC, the insurance subsidiaries, or net cash.

RBI on file for evergreening; $1.5B written off with the explicit framing of 'no P&L impact'.

• The regulator order. On 29 May 2024, RBI ordered ECL Finance and Edelweiss ARC to cease structured-credit activity, citing "evergreening of stressed exposures of ECL using EARCL and connected AIFs." Stock fell 16% the next day. Restrictions were lifted 17 December 2024.
• The accounting question. FY25 carried a $1.5B write-down of EARC trust AUM and a $135M SR markdown at ECL Finance, both reported as having no income-statement effect because earlier fair-value charges had absorbed them. There is no public reconciliation of those earlier charges.
• The bond market dissents. CRISIL placed Edelweiss on A+/Watch Negative in October 2025 — ten months after RBI lifted the curbs. New rupee bonds price at 9.0–10.5% versus ~8.0% for clean A+ peers. When equity and credit disagree on a financial firm, credit usually wins.

The deleveraging is finished. The operating recovery is not.

Borrowings have come down roughly $4.5B in six years — that is what made the post-2023 share-price rally possible. But ROE sits well below the FY19 peak, and the +46% headline PAT growth carries $380M of Nuvama disposal liquidity. Strip the disposals and the underwritable run-rate is closer to $70M a year — which is what the bear is arguing the multiple should price.

Three confirmed events; the densest catalyst stretch in three years.

• 30 April 2026 — Q4 FY26 results. First clean print since SEBI cleared EAAA. Watch underlying PAT ex-disposals (9M run-rate: $50M, +22% YoY) and whether the FY27 insurance break-even target — already slipped twice — gets reaffirmed.
• By 31 July 2026 — Carlyle / Nido close. $225M cash from Carlyle's 45% stake in Nido Home Finance, pending RBI, NHB, and CCI approvals. Aditya Puri (ex-HDFC Bank CEO) co-investing via Salisbury. A regulator-driven delay reads as a signal.
• Through 23 April 2027 — EAAA IPO window. $160M offer-for-sale by an Edelweiss subsidiary; book-runners Axis, Jefferies, Motilal, Nuvama. The price band is the print that flips bull to confirmed or bear to triggered.